Lynn Resnick

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi Targeting JNK3 for the treatment of neurodegenerative disorders
    Lynn Resnick
    Wyeth Research, CN 8000, Princeton, NJ 08543 8000, USA
    Drug Discov Today 9:932-9. 2004
  2. doi Synthesis and structure-activity relationship of a novel series of heterocyclic sulfonamide gamma-secretase inhibitors
    Jun Pu
    Chemical Sciences, Wyeth Research, Princeton, NJ 08543 8000, USA
    Bioorg Med Chem 17:4708-17. 2009
  3. ncbi Asymmetric synthesis of novel alpha-amino acids with beta-branched side chains
    Minsheng Zhang
    Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Bioorg Med Chem Lett 17:2401-3. 2007
  4. doi Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease
    Scott C Mayer
    Chemical and Screening Sciences, and Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, New Jersey 08543, USA
    J Med Chem 51:7348-51. 2008
  5. doi Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2)
    Frank Lovering
    Chemical Sciences, Wyeth Research, Cambridge, MA 02140, USA
    Bioorg Med Chem 17:3342-51. 2009
  6. doi Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist
    Robert H Ring
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Neuropharmacology 58:69-77. 2010
  7. pmc Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease
    Steven P Braithwaite
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Neurobiol Dis 39:311-7. 2010

Collaborators

Detail Information

Publications7

  1. ncbi Targeting JNK3 for the treatment of neurodegenerative disorders
    Lynn Resnick
    Wyeth Research, CN 8000, Princeton, NJ 08543 8000, USA
    Drug Discov Today 9:932-9. 2004
    ..Because of the involvement of JNK3 in neuronal diseases, the inhibition of this enzyme is an attractive therapeutic target...
  2. doi Synthesis and structure-activity relationship of a novel series of heterocyclic sulfonamide gamma-secretase inhibitors
    Jun Pu
    Chemical Sciences, Wyeth Research, Princeton, NJ 08543 8000, USA
    Bioorg Med Chem 17:4708-17. 2009
    ..Several examples of compounds within this series demonstrate a higher propensity to inhibit the processing of amyloid precursor protein compared to Notch, an alternative gamma-secretase substrate...
  3. ncbi Asymmetric synthesis of novel alpha-amino acids with beta-branched side chains
    Minsheng Zhang
    Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Bioorg Med Chem Lett 17:2401-3. 2007
    ....
  4. doi Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease
    Scott C Mayer
    Chemical and Screening Sciences, and Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, New Jersey 08543, USA
    J Med Chem 51:7348-51. 2008
    ..Further side chain modification afforded the potent Notch-1-sparing GSI begacestat (5), which was selected for development for the treatment of Alzheimer's disease...
  5. doi Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2)
    Frank Lovering
    Chemical Sciences, Wyeth Research, Cambridge, MA 02140, USA
    Bioorg Med Chem 17:3342-51. 2009
    ..These squarate based inhibitors were identified via a high-throughput screen. An MK2 co-structure with the starting ligand was obtained and a structure based approach was followed to optimize potency and selectivity...
  6. doi Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist
    Robert H Ring
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Neuropharmacology 58:69-77. 2010
    ..A selective OTR antagonist also failed to block the effects of OT on immobility in the TST. The significance of these findings for shaping the clinical development of OTR agonists is discussed...
  7. pmc Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease
    Steven P Braithwaite
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Neurobiol Dis 39:311-7. 2010
    ..Our findings demonstrate that Abeta can induce neurodegeneration, at least in part, through the JNK pathway and suggest that inhibition of JNK may be of therapeutic utility in the treatment of AD...